EYLEA 8mg for the treatment of neovascular age-related macular degeneration and diabetic macular edemaDecember 9th 2024
Between the Lines: Expanding Treatment Options in Retina Diseases with BiosimilarsApril 18th 2024Expert retina specialists discuss the efficacy and safety data of the ranibizumab biosimilar, SB11, and explore the practical implications of biosimilars in the broader real-world context.